Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182863 | 0.93 | HTR3E (0.53) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL9829333 | 0.89 | POLB (0.53) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL10690612 | 0.85 | ADRB1 (0.59) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL19545461 | 0.84 | L3MBTL1 (0.49) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL28599511 | 0.83 | HTR3E (0.73) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL29656856 | 0.83 | HTR3E (0.73) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL6074493 | 0.82 | KMT2A (0.75) | LMNASMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL14117693 | 0.80 | ADRB1 (0.63) | ADRB1POLBSMN1; SMN2MAPTKMT2A | |
| SCHEMBL9966857 | 0.80 | LMNA (0.60) | POLBL3MBTL1LMNATSHRSMN1; SMN2 | |
| SCHEMBL2925759 | 0.79 | HTR3E (0.68) | HTR3EHTR3BADRB1HTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| WO-2020108579-A1 | AMINO-SUBSTITUTED PYRIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
| CN-107108610-B | Novel tetrahydropyridopyrimidine and tetrahydropyridopyridine compounds for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3240537-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-06-03 | — | — | US | disclosed |
| CN-1141936-C | Usage of aryl-cyclohexylamine derivant in anti-disturbance of central nervous system | - | 2004-03-17 | — | — | CN | disclosed |
| WO-2004004632-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |
| CN-1248439-A | Usage of aryl-cyclohexylamine derivant in anti-disturbance of central nervous system | HOFFMAN LA ROCHE & CO AKTEINGE (DE) | 2000-03-29 | — | — | CN | disclosed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | disclosed |
| US-4774249-A | Pyrimidine derivatives for treating malaria | HOFFMANN-LA ROCHE INC. (US) | 1988-09-27 | — | — | US | disclosed |
| EP-0122580-B1 | PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-10-28 | — | — | EP | disclosed |
| US-4590270-A | 2,4-diamino-[4-piperidinyl]pyrimidines useful as antibacterial agents, antimalarial agents, antitumors agents | HOFFMANN-LA ROCHE INC. (US) | 1986-05-20 | — | — | US | disclosed |
| EP-0122580-A1 | Pyrimidine derivatives, their preparation and pharmaceutical compositions | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | CCNK, CCNI, CDK1 | HTR3E 2315/4885HTR3B 3078/4885ADRB1 1148/4885 |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TPX2, QDPR, TPMT | HTR3E 3597/4885HTR3B 1665/4885ADRB1 1119/4885 |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | TPMT, TYMP, DPYD | HTR3E 3647/4885HTR3B 2117/4885ADRB1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.